AstraZeneca PLC (AZN)

31.71
0.40 1.30
NYSE : Health Care
Prev Close 31.31
Open 31.65
Day Low/High 31.63 / 31.83
52 Wk Low/High 25.55 / 35.04
Volume 1.07M
Avg Volume 5.87M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 79.20B
EPS 1.40
P/E Ratio 14.04
Div & Yield 1.90 (6.10%)

Latest News

European Markets Mixed, Auto Stocks Slide, U.S. Dollar Slumps

European Markets Mixed, Auto Stocks Slide, U.S. Dollar Slumps

European markets are mixed amid a pause in the global equity market rally after a slumping dollar helped Asia shares to their best weekly gain in more than six months.

AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment

AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment

AstraZeneca said Friday that it had received a second "complete response letter" from the U.S. FDA regarding its Hyperkalaemia treatment, putting the drug's approval process in the United States doubt.

Goldman Sachs Raises Clovis Oncology Price Target to $75

Goldman Sachs Raises Clovis Oncology Price Target to $75

Clovis Oncology closed trading below $67 on Tuesday.

Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Stocks declined on Tuesday as wild weather stifled activity and led to low volume.

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.

LYNPARZA™ (olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit In BRCA-Mutated Ovarian Cancer As Maintenance Therapy

LYNPARZA™ (olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit In BRCA-Mutated Ovarian Cancer As Maintenance Therapy

AstraZeneca today presented results from the Phase III SOLO-2 trial demonstrating a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer...

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European healthcare stocks fell Tuesday after President Donald Trump reiterated a vow to reduce drug prices in the United States.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALEX, AZN, BDL, INGN, ITRI, PAH Downgrades: AGYS, ASFI, IKNX, PRFT, SIX, VNCE Initiations: SRG Read on to get TheStreet Quant Ratings' detailed report:

Wake Up Wall Street: Donald Trump to Address Congress

Wake Up Wall Street: Donald Trump to Address Congress

U.S. stock futures and shares in Europe and Asia trade mixed Tuesday ahead of Donald Trump's first speech to a joint session of Congress.

Global Financial News: Nikkei 225 Snaps Losing Streak

Global Financial News: Nikkei 225 Snaps Losing Streak

Markets in Asia attempted to bridge the gap between U.S. and European markets overnight before paring gains as the session wound to a close

European Stocks Hold Cautious Gains Ahead of U.S Data, Trump Address to Congress

European Stocks Hold Cautious Gains Ahead of U.S Data, Trump Address to Congress

European stocks struggled to hold on to gains Tuesday as investors adopted cautious positioning ahead of key U.S. economic data and the first address to Congress by President Donald Trump.

AstraZeneca Shares Rise After FDA Approval for Type-2 Diabetes Treatment

AstraZeneca Shares Rise After FDA Approval for Type-2 Diabetes Treatment

AstraZeneca stock gained in early London trading Tuesday after it received approval from the U.S. Food and Drug Administration for a type-2 diabetes medication.

FDA Approves Once-Daily QTERN® (Dapagliflozin And Saxagliptin) Tablets For Adults With Type-2 Diabetes

FDA Approves Once-Daily QTERN® (Dapagliflozin And Saxagliptin) Tablets For Adults With Type-2 Diabetes

AstraZeneca (NYSE:AZN) today announced that the US Food and Drug Administration (FDA) has approved once-daily QTERN ® (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

AstraZeneca Has Started a Turnaround

AstraZeneca Has Started a Turnaround

The old saying that volume precedes price could be playing out

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Dow, S&P 500 and Nasdaq Close Out Strong Week With Fresh Records

Dow, S&P 500 and Nasdaq Close Out Strong Week With Fresh Records

The Dow, S&P 500 and Nasdaq rose slightly on Friday ahead of the long holiday weekend.

Stocks Hold Mixed in Unsettled Session as Record Rally Ends

Stocks Hold Mixed in Unsettled Session as Record Rally Ends

Wall Street is mixed in a quieter end to a record-breaking week in which stocks scored their best winning streak in a quarter century.

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

European Benchmarks Fall, But London Bucks Trend on Takeover Activity

European Benchmarks Fall, But London Bucks Trend on Takeover Activity

Kraft Heinz's offer for Unilever boosted the FTSE 100 in London, but markets were in the red elsewhere.

Stocks Drift Lower in Quieter Trading After the Week's Record Run

Stocks Drift Lower in Quieter Trading After the Week's Record Run

Wall Street is mostly lower in a quieter end to a record-breaking week in which stocks scored their best winning streak in a quarter century.

Wall Street Looks Set to Open Lower as Stock Futures Retreat Again

Wall Street Looks Set to Open Lower as Stock Futures Retreat Again

Stock futures retreat again on Friday, looking to close out the week on a bum note following Wall Street's best record-breaking run in a quarter century.

AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial

AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial

Astrazeneca stock rose Friday after the company said that its Lynparza drug fared well in clinical trials of its effectiveness as a breast cancer treatment.

LYNPARZA™ (olaparib) Meets Primary Endpoint In Phase III Trial In BRCA-Mutated Metastatic Breast Cancer

LYNPARZA™ (olaparib) Meets Primary Endpoint In Phase III Trial In BRCA-Mutated Metastatic Breast Cancer

AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA™ (olaparib) tablets (300mg twice daily) to physician's choice of a standard of care chemotherapy in the treatment of...

European Benchmarks Fall on Weak Earnings and Ex-Dividends

European Benchmarks Fall on Weak Earnings and Ex-Dividends

Weak earnings and ex-dividend dates drove a correction in stock markets across Europe.